Lysin Bio
Lysin Bio is a South Korea-based synthetic biology company developing bacteriophage-derived endolysins and engineered live biotherapeutic products (eLBPs) as antibiotic alternatives for livestock feed additives, with pipeline expansion into cosmeceutical, companion animal, and human pharmaceutical applications.
- Company typePrivate
- Founded2021
- HeadquartersDaejeon, South Korea
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What Lysin Bio does
Lysin Bio (LysinBIO Corporation, 주식회사 리신바이오) is a South Korea-based synthetic biology drug development company founded in October 2021 and headquartered in Daejeon, with an R&D and production facility at the Iksan Green Bio Venture Campus. The company develops antibiotic alternatives using two proprietary platforms: recombinant endolysins derived from bacteriophages that enzymatically degrade bacterial cell walls, and Engineered Live Biotherapeutic Products (eLBPs) that use GRAS probiotic strains to orally deliver endolysins targeting antibiotic-resistant bacteria. Its commercial product line, the PhagePlus series (PhagePlus-S for Salmonella, PhagePlus-E for E. coli, PhagePlus-SA for Staphylococcus aureus), was registered as livestock feed ingredients in April 2026 and is sold directly to livestock farms as antibiotic replacements.
Lysin Bio generates revenue through direct B2B feed additive sales to livestock integrators (its primary commercial channel), with potential future revenue from licensing its eLBPs and endolysin platforms to pharmaceutical partners and from R&D services. The company is also pursuing adjacent verticals including cosmeceuticals (C. acnes bacteriophage ingredients for acne treatment), companion animal therapeutics (joint development with KR Lab Bio), and human pharmaceutical applications for antibiotic-resistant infections including Helicobacter pylori. Distribution is currently domestic through direct enterprise sales, with a planned Southeast Asia expansion via a joint venture with Singapore-based Invitroque.
The company is venture-backed, having received seed investment from Daedeok Venture Partners (December 2021) and Altoran Ventures (November 2025), corporate strategic investments from Daehan Newpharm (December 2024 and May 2025), government R&D funding through the TIPS program (500M+ KRW) and BIG3 project (600M KRW), and a growth sharing fund from the SME Venture Promotion Agency. It holds three granted Korean patents covering recombinant endolysins and transgenic endolysin-producing Bacillus subtilis strains, plus a PCT international application. Lysin Bio is preparing for a KOSDAQ listing with IBK Investment Securities engaged as lead underwriter since May 2023.
Lysin Bio firmographics
Firmographics- Name
- Lysin Bio
- Legal name
- 주식회사 리신바이오
- Website
- https://lysinbio.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Short description
- Lysin Bio is a South Korea-based synthetic biology company developing bacteriophage-derived endolysins and engineered live biotherapeutic products (eLBPs) as antibiotic alternatives for livestock feed additives, with pipeline expansion into cosmeceutical, companion animal, and human pharmaceutical applications.
- Ownership category
- akta.pro rank
Lysin Bio industry classification
Industry- Product category
- Biotechnology - Antibiotic Alternatives
- NAICS
- Animal Food Manufacturing (3111), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Food And Kindred Products (2000), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Non-Antibiotic Health & Performance Supplements (Immune, Gut Health, Stress/Heat Support) (AFADALAO)
- akta.pro secondary industries
- Probiotics, Prebiotics & Postbiotics (Direct-Fed Microbials) (AFADALAE), Nutraceuticals & Functional Ingredients for Animal Diets (Probiotics, Omega-3, Joint, GI) (HLAMAHAH), Probiotics, Prebiotics & Synbiotics (AFADAKAC)
Keywords
Where Lysin Bio is headquartered
LocationHeadquarters
- HQ city
- Daejeon
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
Lysin Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Feed Additive Sales: Sale of bacteriophage-based feed additives (Phage Plus product line) for livestock as antibiotic alternatives. Registered as feed ingredient manufacturer (보조사료 제조업) and generates recurring revenue from livestock industry customers.
- Licensing and Technology Transfer: The company develops proprietary technology platforms (eLBPs, endolysin) that can be licensed to pharmaceutical partners for human and animal drug development.
- R&D Services and Partnerships: Collaborative research and development with strategic partners including pharmaceutical companies, universities, and research institutions, potentially generating milestone and royalty payments.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Lysin Bio product offering
Product offeringCore offering
Lysin Bio develops and manufactures bacteriophage-based feed additives (PhagePlus-S, PhagePlus-E, PhagePlus-SA) as antibiotic alternatives for controlling Salmonella, E. coli, and Staphylococcus aureus in livestock. The company leverages two proprietary platforms: recombinant endolysin technology derived from bacteriophages and eLBPs (Engineered Live Biotherapeutic Products), which uses GRAS probiotic strains for oral delivery of endolysin proteins to target antibiotic-resistant bacteria.
Product overview
Lysin Bio is a synthetic biology-based drug development company focused on antibiotic alternatives. The core product portfolio includes the PhagePlus series of bacteriophage cocktails (PhagePlus-S, PhagePlus-E, PhagePlus-SA) targeting Salmonella, E. coli, and Staphylococcus aureus respectively, registered as feed ingredients for livestock antibiotic replacement. Underlying these products is the eLBPs (Engineered Live Biotherapeutic Products) platform technology - a GRAS-based oral drug delivery system that leverages probiotic bacteria to produce endolysins targeting antibiotic-resistant bacteria. The company also develops recombinant endolysin-based protein drugs and is expanding into cosmeceutical applications for acne treatment.
Differentiator
Problem solved
Functional benefit
Products and services
- PhagePlus-S (파지플러스-에스) Bacteriophage cocktail targeting Salmonella species (S. Gallinarum, S. Typhimurium, S. Enteritidis) for use as a feed additive antibiotic alternative in livestock production.
- PhagePlus-E (파지플러스-이) Bacteriophage cocktail for effective control of E. coli in livestock as an antibiotic alternative feed additive.
- PhagePlus-SA (파지플러스-에스에이) Bacteriophage cocktail for controlling Staphylococcus aureus in livestock as an antibiotic alternative feed additive.
- eLBPs (Engineered Live Biotherapeutic Products) GRAS strain-based oral drug delivery platform using engineered probiotic bacteria to produce endolysins that kill specific antibiotic-resistant bacteria. Eliminates the need for repeated injections and reduces side effects of conventional treatments. Platform supports human pharmaceutical, companion animal, and cosmeceutical applications.
Quantifiable outcome
- Zero new AMR antibiotic developments since 1970s, creating urgent market need
- +1 more outcomes
Companies that use Lysin Bio
Customer profileSegments3 records
Ideal customer profiles3 records
Lysin Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Lysin Bio partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered major, minor and core.
- InvitroquemajorSingapore biotech company Invitroque signed LOI (Letter of Intent) with LysinBIO for overseas business cooperation. Plans include expansion into Thailand and other Southeast Asian markets for livestock antibiotic alternatives, and establishment of Joint Venture (JV).
- Korea Agriculture Technology Promotion Agency / Painters & Ventures (한국농업기술진흥원 / 페인터즈앤벤처스)minorSelected for '2026 Jeollabuk-do Green Bio Specialized Accelerator Cultivation Support (daVinci Green BIO)' program jointly organized by Korea Agriculture Technology Promotion Agency and Painters & Ventures to strengthen innovation growth and global expansion capabilities in green bio sector.
- Xylonix (자이로닉스)majorSingapore-based pharmaceutical company Xylonix (representative: Dr. Jung Jin-hyuk) signed a strategic partnership with LysinBIO for potential collaboration in antibiotic alternative development.
- KR Lab Bio (케이알랩바이오)coreMOU signed with KR Lab Bio (representative: Noh Gyu-hyung) for comprehensive cooperation in developing super antibiotics for companion animals (pets). Collaboration includes joint development, joint marketing, and overseas expansion.
- Seoul National University Bundang Hospital (분당 서울대학교병원)minorSelected for K-Bio Health Regional Center Support Project, receiving clinical mentor program support from Infectious Disease Department physicians to guide R&D direction and strategy for protein new drugs.
- Korea Research Institute of Bioscience and Biotechnology (KRIBB, 한국생명공학研究院)coreSelected for Daedeok Science Town Bio-Health Technology Business Collaboration Platform project. KRIBB identifies innovative technology-based bio companies for family company designation and provides multi-faceted cooperation and support.
- Kaimi (카이미)minorMOU with Kaimi (representative: Professor Jung Jun-won, Gastroenterology Dept., Gachon University Gil Hospital) for development of novel antibiotics for treating antibiotic-resistant Helicobacter pylori.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Lysin Bio competitors and assessment
Company assessmentDirect peers
- ContraFect Corporation: Clinical-stage biotech developing direct lytic agents (endolysins and amurin peptides) for serious infections, including antibiotic-resistant bacteria. Most direct technological comparable to Lysin Bio's recombinant endolysin platform.
- Micreos: Phage-based technology company with products across human and animal health, including agricultural and food applications. Direct overlap with Lysin Bio's bacteriophage-based antibiotic alternative positioning.
- Intralytix, Inc. US-based biotechnology company developing bacteriophage-based products for food safety, animal health, and human therapeutics. Closely aligned to Lysin Bio's bacteriophage cocktail approach (PhagePlus line).
- Phagelux (Phibro Animal Health): Bacteriophage products for animal health and aquaculture, acquired by Phibro Animal Health. Competes directly in the livestock phage feed-additive market that is Lysin Bio's primary commercial focus.
Broad incumbents
- Elanco Animal Health: Global animal health company offering antibiotics, vaccines, and feed additives for livestock. A potential competitor and acquisition partner for Lysin Bio's antibiotic-replacement portfolio in livestock.
- CJ CheilJedang (Animal Feed): Korean conglomerate with large animal feed and livestock nutrition business. Broad incumbent in the same end market (livestock feed) that Lysin Bio serves with its bacteriophage feed additives.
Emerging players
- Pherecydes Pharma: French clinical-stage company developing phage therapy candidates targeting antibiotic-resistant infections. Comparable in therapeutic intent to address AMR, though focused on human applications.
- Eligo Bioscience: French biotech developing phage-derived 'eligobiotics' — engineered payloads delivered by phages — for microbiome editing and antimicrobial applications. Comparable eLBP-like delivery paradigm to Lysin Bio's platform.
- Locus Biosciences: Developer of engineered phage and endolysin-based antimicrobials for antimicrobial-resistant pathogens. Closely aligned with Lysin Bio's synthetic biology + endolysin focus area.
- BiomX Inc. Clinical-stage company using phage cocktails to target specific bacteria in diseases such as acne and IBD. Comparable in targeting specific pathogenic bacteria with phage cocktails, including an acne cosmeceutical application that overlaps with Lysin Bio's cosmeceutical pipeline.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights7 records
Customer concentration
Lysin Bio social profiles
Digital presenceLysin Bio compliance and trust
Trust signalCompliance8 records
Lysin Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lysin Bio leadership team
Management profileNumber of profiles
Profiles1 record
Lysin Bio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lysin Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lysin Bio
What does Lysin Bio do?
Lysin Bio develops and manufactures bacteriophage-based feed additives (PhagePlus-S, PhagePlus-E, PhagePlus-SA) as antibiotic alternatives for controlling Salmonella, E. coli, and Staphylococcus aureus in livestock. The company leverages two proprietary platforms: recombinant endolysin technology derived from bacteriophages and eLBPs (Engineered Live Biotherapeutic Products), which uses GRAS probiotic strains for oral delivery of endolysin proteins to target antibiotic-resistant bacteria.
Is Lysin Bio a public or private company?
Lysin Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Lysin Bio founded?
Lysin Bio was founded in 2021.
Where is Lysin Bio based?
Lysin Bio is headquartered in Daejeon, South Korea, in the Asia region.
How does Lysin Bio make money?
Three revenue lines are on record. Feed Additive Sales are the primary driver. The others are licensing and Technology Transfer and R&D Services and Partnerships.
Who are Lysin Bio's main competitors?
Direct peers on record are ContraFect Corporation, Micreos, Intralytix, Inc. and Phagelux (Phibro Animal Health). Broad incumbents are Elanco Animal Health and CJ CheilJedang (Animal Feed). Emerging players are Pherecydes Pharma, Eligo Bioscience, Locus Biosciences and BiomX Inc..
Does Lysin Bio have an API?
No public API is recorded for Lysin Bio.
What industry is Lysin Bio in?
Lysin Bio's product category is Biotechnology - Antibiotic Alternatives. Its primary akta.pro industry code is AFADALAO, Non-Antibiotic Health & Performance Supplements (Immune, Gut Health, Stress/Heat Support), with a secondary code of AFADALAE, Probiotics, Prebiotics & Postbiotics (Direct-Fed Microbials). Its NAICS code is 3111 and its SIC code is 2000.